Short version: Tuberculosis (TB) is curable in most cases if you use the right medicines, for the right length of time, and take them exactly as prescribed. The longer versionwell, that’s this article. Buckle up (and take your B6 if you’re on isoniazid).

What We Mean by “Latent,” “Active,” and “Drug-Resistant” TB

Latent TB infection (LTBI) means your immune system is keeping Mycobacterium tuberculosis on a tight leashyou’re not sick and you can’t spread it. Treating LTBI lowers your lifetime risk of developing active TB disease. Active TB disease means the bacteria are replicating, you have symptoms, and you can transmit TB (especially with pulmonary TB). Drug-resistant TB (DR-TB) means the bacteria have learned some frustrating tricks against our usual medicinesranging from rifampin-resistant (RR-TB) and multidrug-resistant (MDR-TB) to extensively drug-resistant (XDR-TB).

Latent TB Infection: Shorter, Safer Regimens Are Preferred

In the United States, health authorities prefer short-course, rifamycin-based regimens because they’re easier to finish (and completion is half the battle). The top options include:

• 3HP: once-weekly isoniazid + rifapentine for 12 doses over 3 months.
• 4R: daily rifampin for 4 months.
• 3HR: daily isoniazid + rifampin for 3 months.

These are generally favored over 6–9 months of isoniazid alone because they’re shorter and patients are more likely to complete themmeaning better protection against future TB.

Who Should (and Shouldn’t) Take 3HP?

3HP is recommended for most people aged ≥2 years, including many with HIV if their antiretroviral therapy (ART) plays nicely with rifapentine. It’s not recommended for children <2 years, people with suspected isoniazid or rifampin resistance, or those who are pregnant or expect to become pregnant during the 3 months. For people with HIV on interacting ART, choose a different regimen.

Pregnancy and LTBI

Isoniazid and rifampin are considered acceptable during pregnancy when treatment is indicated; add pyridoxine (vitamin B6) to reduce neuropathy risk. However, 3HP (isoniazid + rifapentine) is not recommended in pregnancy due to limited safety dataopt for alternatives like 4R or isoniazid-based regimens when treatment can’t be deferred.

Directly Observed Therapy (DOT) vs Self-Administered Therapy (SAT)

Short regimens thrive when patients actually finish them (shocking, we know). DOT can boost completion, but many LTBI programs successfully use self-administered therapyespecially with 4Rprovided there’s good education and follow-up.

Active, Drug-Susceptible TB: Start with Four Drugs, Then Tailor

When TB is active (especially pulmonary), start treatment promptly with a four-drug regimen while awaiting susceptibility results: isoniazid (H), rifampin (R), pyrazinamide (Z), and ethambutol (E). Once the isolate proves susceptible, ethambutol is usually dropped. Traditional total durations are 6 months (2HRZE + 4HR), with a 7-month continuation in a few scenarios.

Newer U.S. Guidance: 4-Month Regimens for Selected Patients

Updated U.S. recommendations now include 4-month options for many with drug-susceptible pulmonary TB, and an even shorter 4-month regimen for many children with non-severe disease. Regimen eligibility depends on site of disease, drug susceptibility, and potential drug interactions. Always follow the latest ATS/CDC/ERS/IDSA guidance and your health department’s advice.

TB/HIV Co-Treatment

Rifamycins (rifampin, rifapentine, rifabutin) are potent enzyme inducersthey can tangle with ART. For example, patients on rifamycin-containing TB therapy may require dolutegravir 50 mg twice daily (rather than once daily) during the rifamycin phase, depending on the ART backbone and CD4 count. Specialized tables exist for managing these interactionsuse them. In selected patients with HIV (CD4 ≥100/µL and no problematic DDIs), a 4-month rifapentine-moxifloxacin regimen is an option.

Drug-Resistant TB (DR-TB): Modern Regimens and Safety

For rifampin-resistant or multidrug-resistant TB, U.S. practice increasingly uses bedaquiline-based regimens, often alongside linezolid andwhen indicatedpretomanid (the BPaL regimen) in narrowly defined situations. Pretomanid-containing regimens require careful selection and expert oversight; they’re not “one-size-fits-all” and eligibility criteria are strict.

What About WHO’s Ultra-Short Regimens?

Globally, data support several shorter all-oral regimens (e.g., 6–9 months) using combinations of bedaquiline, linezolid, delamanid, and others. U.S. adoption lags because of regulatory status, population differences, and programmatic considerationsbut the trend is clear: safer, shorter, all-oral DR-TB therapy is here.

Safety Watch: Bedaquiline and Friends

Bedaquiline improves outcomes in DR-TB but prolongs the QT intervalespecially when combined with other QT-prolonging agents (e.g., clofazimine, certain fluoroquinolones). FDA labeling stresses ECG monitoring and attention to drug interactions. Linezolid brings risks of cytopenias and neuropathy; pretomanid has its own cautions and must be used within defined combination regimens. Close monitoring is not optional.

Side Effects & Monitoring You Should Actually Know

• Isoniazid (INH): Risk of hepatitis and peripheral neuropathy. Pyridoxine (vitamin B6) is routinely given in pregnancy, diabetes, HIV, malnutrition, alcohol use, or neuropathy risk.
• Rifampin/Rifapentine: Turns urine, tears, and sweat orange (really); induces CYP enzymes, causing many drug interactions (warfarin, oral contraceptives, azoles, many HIV meds).
• Pyrazinamide: Hepatotoxicity and hyperuricemia; baseline liver tests and uric acid are often checked.
• Ethambutol: Rare optic neuropathy; watch for changes in visual acuity or color visionprompt evaluation if symptoms occur.

How Long Does Treatment Take?

LTBI: Usually 3 or 4 months (sometimes 6 or 9 months of INH if rifamycins aren’t an option). Drug-susceptible active TB: 4 to 6 months in many cases, provided criteria for shorter regimens are met; some situations still need 6–9 months. DR-TB: Often 6–12 months or more, depending on regimen and response. As ever: follow susceptibility results and guideline specifics.

Special Situations

Pregnancy (Active TB)

Treat active disease even in the first trimester. INH, RIF, and EMB are commonly used; add B6 when using INH. Pyrazinamide use is individualized in U.S. practice. Discuss risks and benefits with an expert.

TB & HIV

Coordinate TB and HIV regimens carefully. Timing ART initiation and adjusting doses (e.g., dolutegravir BID with rifamycins) can be crucial to outcomes. Use up-to-date interaction charts from CDC/NIH or IDSA.

Liver Disease or Many Medications

Hepatotoxicity risk may influence regimen design and monitoring frequency. Rifamycins interact with lots of drugs, including hormonal contraceptiondiscuss backup contraception methods.

Practical Tips to Actually Finish Treatment

• Don’t skip doses. Missing early doses is like skipping the intro to a mysterynothing makes sense afterward.
• Ask about interactions (HIV meds, warfarin, azoles, seizure meds, transplant meds, hormonal contraception, and more).
• Report symptoms promptly: jaundice, severe nausea, numb feet, blurry vision, palpitations.
• Use DOT or enhanced support if adherence is toughshort regimens give you fewer hurdles to clear.

Frequently Asked (and Totally Reasonable) Questions

“When am I no longer contagious?”

With pulmonary TB, many patients stop being infectious a few weeks after starting effective therapy and demonstrating clinical improvement, but decisions are individualized and depend on smear/culture status and public health guidance.

“Can I work or go to school?”

Your provider and local health department will advise based on your infectiousness, symptoms, and response to treatment.

“What if I can’t take rifampin?”

Alternatives exist (e.g., isoniazid-based LTBI regimens; tailored active TB regimens). You’ll need a customized plan from a TB-experienced clinician.

Conclusion

Treating TB successfully in 2025 is about precision (pick the right regimen), partnership (coordinate with public health), and persistence (finish the course). LTBI therapy prevents future disease; active TB therapy cures the current episode; modern DR-TB therapy is safer and shorter than it used to be, but demands close monitoring. If you remember only one thing: don’t stop early unless your care team tells you to.

SEO Goodies

sapo: Tuberculosis is curablebut only with the right plan. This guide walks you through today’s U.S.-preferred regimens for latent TB infection, first-line therapy for active disease (including 4-month options), and modern approaches to drug-resistant TB with bedaquiline-based combinations. We also cover pregnancy, HIV drug interactions, side effects worth knowing (hello, orange pee), and practical tips to help you finish strong.

Appendix: Quick Reference Tables

Preferred LTBI Regimens (Adults & Children ≥2 y)

• 3HP: INH + rifapentine weekly × 12 doses (avoid in pregnancy; check ART interactions).
• 4R: Rifampin daily × 4 months (often easier for self-administration).
• 3HR: INH + rifampin daily × 3 months.

Standard Active TB, Drug-Susceptible (Pulmonary)

• Classic: 2HRZE → 4HR (6 months total).
• Shorter options: Selected 4-month regimens for eligible adults and many children with non-severe diseasesee current ATS/CDC/ERS/IDSA guidance.

Drug-Resistant TB

• Bedaquiline-based regimens with companion drugs; in defined patients, BPaL (bedaquiline + pretomanid + linezolid) may be considered under expert guidance. Monitor QT interval and hematologic toxicity.

of Real-World Experience: What It’s Like to Navigate TB Treatment

(The following is a composite of common experiences from patients, caregivers, and cliniciansno personal medical advice.)

Most people with latent TB infection find that the hardest part isn’t side effectsit’s remembering to take the pills and finish the course. A community nurse once joked that “3HP is 12 dates with your pillbox.” Patients who set weekly phone alarms, pair doses with a routine (Sunday dinner), and keep a simple check-off calendar usually glide through. When rifapentine or rifampin turns body fluids orange, it can be alarming for exactly one restroom breakafter that, it becomes a quirky badge of courage. The bigger challenges are often logistical: refills, a missed clinic visit, or confusion about whether to reschedule a dose when you have a cold. Good programs give you a living, breathing contact number and encourage you to call with “silly” questions (they aren’t silly).

With active, drug-susceptible TB, the first two weeks are a blur of tests, masks, and new routines. People are often surprised how quickly they feel bettersometimes within a couple of weeksyet that’s exactly when motivation can dip. Clinicians emphasize that feeling better is the worst time to coast: the bacteria that remain are the stubborn ones, and cutting therapy short is how resistance happens. A respiratory therapist described a patient who set up a “pill station” by the coffee maker: meds in a labeled box, water bottle, and a sticky note with the day’s doses. Side effects happenmild nausea, a stray headachebut most are manageable with timing tweaks or snacks. Any warning signs (jaundice, severe nausea, numb fingers, new vision changes) prompt an immediate call. Patients hear that ethambutol eye changes are rare, but the rule is simple: if you notice color looking “off” or words fuzzier on the page, say something right away.

Drug-resistant TB demands more patience and more teamwork. One pharmacist calls the regimen a “living document”ECGs, blood counts, and potential drug interactions mean plans evolve. People on bedaquiline learn about QT monitoring early, and clinics often schedule ECGs to coincide with medication pickups to cut travel time. Others on linezolid quickly learn to report tingling hands or unusual fatigue. The good news is that today’s DR-TB care is much kinder than a decade ago: all-oral options, fewer injections, and shorter courses are changing the experience from an endurance trial to a structured marathon with water stations every mile. Patients who keep a simple diary of doses and symptoms often become the most empowered; they walk into clinic able to say, “Week three: two dizzy spells; week four: none.” That specificity helps the team tune therapy rather than stop it.

Across all scenarios, the thread is support. DOT (or its modern cousins using video check-ins) isn’t about policingit’s about having someone in your corner to problem-solve early. If you’re pregnant or living with HIV, you’ll meet extra specialists, and that can feel overwhelming. Most patients ultimately appreciate the “village” approach: the TB clinician watches your lungs; the HIV specialist adjusts ART to avoid rifamycin collisions; the pharmacist tracks interactions that no human should have to memorize. The takeaway from countless journeys is hopeful and practical: TB has a cure, and the path is walkable with a map, a team, and a steady pace.

The post Treatments for Tuberculosis: Latent, Active, and Drug-Resistant appeared first on Everyday Software, Everyday Joy.

Tuberculosis (TB) sounds like something out of an old history book, wedged between “black-and-white photos” and “people wearing top hats.”
But the latest data say otherwise. After nearly three decades of decline, TB cases in the United States have been climbing again since 2021
and the most worrying uptick is among children and young teens.

In 2023, the U.S. reported 9,615 TB cases, a 16% jump from 2022 and the highest number since 2013. Provisional numbers for 2024 are even higher,
with more than 10,300 cases and an 8% increase over 2023.
Every age group saw an increase, but the largest relative jump was among kids ages 5–14. Suddenly, a disease many people thought was “gone”
is very much back on the public health radar especially for families.

The good news? TB is preventable, testable, and curable with the right care. The less-good news is that rising cases mean we have to stop
treating TB like an old-timey problem and start treating it like what it is: a modern, ongoing threat that disproportionately affects the most vulnerable,
including young children.

What the Latest Numbers Really Show

Let’s unpack the data behind the headlines. According to the Centers for Disease Control and Prevention (CDC), TB incidence increased across
every age group in 2023, but children 5–14 years old had the sharpest relative rise in both case counts and rates.
While adults still account for most TB cases, this spike in pediatric and young adolescent cases is a loud warning signal: kids are getting infected
in the here and now, not just in faraway places or distant decades.

Geographic patterns tell a similar story. States like California and Texas have seen substantial increases in TB since 2020, returning to or exceeding
pre-pandemic levels. Major cities such as New York City also reported their highest TB numbers in years,
with growing concerns about cases in young children and other high-risk groups.

Provisional national data for 2024 show more than 10,300 cases the highest numbers in over a dozen years with increases in 34 states and
the District of Columbia. These bumps are not random; they track with broader shifts in global travel,
migration, and the lingering effects of the COVID-19 pandemic on healthcare systems.

Why Are TB Cases Rising Again?

TB hasn’t suddenly become more contagious or “stronger” as a bacteria. Instead, multiple overlapping trends are nudging case numbers upward:

1. Pandemic Disruptions to Health Services

During the COVID-19 pandemic, routine healthcare visits, screenings, and public health outreach all took a hit. Globally, TB programs reported
fewer diagnoses and more treatment interruptions between 2020 and 2022.
When people aren’t tested or treated on time, TB doesn’t politely pause it keeps spreading quietly in communities.

2. Increased Travel and Migration

TB is far more common in many parts of the world than it is in the U.S., so global travel and migration significantly shape U.S. case patterns.
Most people diagnosed with TB in recent U.S. data were born outside the country, often in regions where TB is endemic.
As international travel rebounded after COVID, opportunities for TB exposure and importation increased too.

3. Latent TB Becoming Active

The CDC estimates that up to 13 million people in the U.S. may have latent TB infection meaning the bacteria are present but “sleeping” in the body.
These individuals are not sick and can’t spread TB, but if their immune systems weaken, the infection can reactivate and become contagious.
Conditions like diabetes, HIV, cancer therapies, and certain immune-suppressing medications all raise the risk of latent TB waking up.

4. Unequal Access to Care and Public Health Resources

TB doesn’t affect everyone equally. Communities of color, people experiencing homelessness, those in congregate settings (shelters, prisons,
long-term care facilities), and immigrants often face the greatest TB burden.
Local public health departments the teams that do TB testing, contact tracing, and treatment follow-up report struggling to keep up as funding
and staffing lag behind rising caseloads.

Why Young Children Are Especially Vulnerable

TB in children is a double red flag: it’s both a serious health threat for the child and a sign that transmission is happening in the community right now.
Pediatric TB usually indicates that a child has had close, sustained contact with an infectious adult, often in the same household or daycare setting.

Biologically, kids are not just “small adults.” Young immune systems react differently to TB bacteria:

• Infants and toddlers are at much higher risk of developing severe forms of TB such as TB meningitis or widespread (miliary) TB
  shortly after infection.
• School-age children (5–14) typically have lower overall risk than infants, but current U.S. data show the fastest relative increase
  in TB rates in this group, meaning more infections are being detected than before.
• Adolescents begin to resemble adults in both disease patterns and infectiousness, and they can play a larger role in spreading TB.

When you see TB in a young child, you can almost always assume there is at least one adult with active TB somewhere in that child’s orbit.
That’s why pediatric TB is often described as a “sentinel event” a warning sign that public health systems need to find and treat hidden
adult cases quickly.

How TB Spreads: A Quick Refresher

TB is caused by the bacteria Mycobacterium tuberculosis and usually affects the lungs, though it can also involve the brain, spine, kidneys,
or other organs. It spreads through the air via tiny droplets when someone with active pulmonary TB coughs, laughs, speaks loudly, or sings.

A few important clarifications for worried parents:

• TB is not spread by shaking hands, sharing dishes, touching doorknobs, or casual brief contact.
• It usually requires prolonged close contact think living in the same household or spending many hours together in enclosed spaces.
• Many people who are infected never develop active disease; their infection remains latent unless their immune system weakens.

Signs and Symptoms Parents Should Know

TB can be sneaky, especially in children. Symptoms may develop slowly and look like a stubborn version of something else.
Always talk with a healthcare professional for specific advice, but common signs of pulmonary TB include:

• Cough lasting three weeks or longer
• Fever that lingers or keeps coming back
• Night sweats (waking up with damp or soaked pajamas or sheets)
• Unintentional weight loss or poor weight gain
• Fatigue, unusual sleepiness, or decreased activity
• Chest pain or trouble breathing
• Coughing up blood (less common in children but always an emergency sign)

In very young children, symptoms can be less specific irritability, poor feeding, or just “not acting like themselves.”
Any child who has had close contact with someone diagnosed with TB, especially in the home, should be evaluated even if they feel well.

How TB Is Diagnosed and Treated Today

The days of diagnosing TB purely by waiting for an old-school skin test and chest X-ray are largely gone. Today, clinicians can use:

• TB skin tests (TST), often used in schools, workplaces, or for routine screening.
• Blood tests (IGRAs), which can be particularly helpful in people who received the BCG vaccine outside the U.S.
  and might have false-positive skin test results.
• Chest X-rays and imaging, to look for lung changes suggestive of active TB disease.
• Sputum or other specimen tests, including rapid molecular tests that can detect TB bacteria and some drug resistance patterns.

TB is highly treatable with antibiotics, but treatment is not a quick course of pills. Most regimens for active TB last at least 4–6 months and
use multiple drugs at once to prevent resistance. Children can be treated with age-appropriate dosing and careful monitoring for side effects.
Drug-resistant TB requires more complex regimens, but effective options still exist when specialist care is available.

For latent TB infection, shorter preventive regimens some as brief as 3–4 months have become more common, making it easier
for families to complete treatment and reduce the risk of future disease.

What Families Can Do: Practical, Real-World Steps

You don’t need to become a TB expert overnight, but you can take a few thoughtful steps to protect your family:

1. Know Your Risk Factors

Talk with your child’s healthcare provider if your family has:

• Lived or spent extended time in a country where TB is common
• Had close contact with someone diagnosed with TB disease
• Children with conditions that weaken the immune system
• Household members who live or work in shelters, correctional facilities, or long-term care centers

In these situations, TB testing (often a blood test) may be recommended even if everyone feels perfectly fine.

2. Take Exposure Seriously, Not Silently

If a school, daycare, or health department notifies you that your child may have been exposed to TB, it’s not a reason to panic but it definitely
is a reason to follow up. Testing, follow-up appointments, and (if needed) preventive treatment are how you turn a scary letter into a success story.

3. Support Treatment to the Finish Line

TB therapy is a marathon, not a sprint. Stopping medications early is one of the biggest risk factors for recurrence and drug-resistant TB.
Many public health programs offer directly observed therapy (DOT) or “video DOT,” reminders, and other support to help families stay on track.

4. Remember the Big Picture: TB Is Curable

Rising numbers can sound alarming, but the takeaway for parents isn’t “be afraid of everyone.” It’s “be informed, be proactive, and partner with
healthcare and public health teams.” When TB is found early and treated correctly, kids can and do recover fully.

Public Health Response: Why Your Voice Still Matters

TB control depends heavily on public health infrastructure the mostly invisible systems that make sure screening, lab testing, contact tracing,
and medication programs keep moving. Experts have warned that even as TB cases rise, many health departments don’t have the resources they need
to keep up.

At the same time, global TB remains a massive challenge. In 2023, TB again became the world’s leading infectious disease killer, with millions of
new cases and over a million deaths, including many children under 5.
What happens abroad doesn’t stay abroad global TB trends eventually ripple into U.S. communities through travel, migration, and shared health systems.

That’s why advocacy matters. Funding for TB programs, both in the U.S. and worldwide, directly affects our ability to protect vulnerable groups,
including American children. When parents, clinicians, and communities push for sustained investment in TB prevention and care, they’re not just
supporting anonymous “public health work” they’re protecting actual kids in real neighborhoods.

Real-World Experiences: How Families and Clinicians Are Living This

Statistics tell one part of the story; everyday experiences tell the rest. The following examples are composites based on common patterns described
by clinicians and public health workers not accounts of any single identifiable person but they capture what rising TB cases look like on the ground.

A Pediatric Clinic’s Wake-Up Call

In one community clinic, TB had been a “background topic” for years mentioned in training, occasionally tested for, rarely seen. Then, over the
span of a few months, providers started noticing a pattern: a 9-year-old with a lingering cough and low-grade fevers; a 12-year-old who kept losing weight;
a toddler with unexplained fevers and a concerning chest X-ray. None of them looked like the dramatic textbook cases, but something didn’t add up.

As the clinic began testing more aggressively, they uncovered multiple cases of TB infection and a few active cases linked to a single extended family.
Public health teams stepped in, testing household members, school contacts, and caregivers. Within weeks, dozens of people had been evaluated. Several
children started preventive treatment, while a few adults began full TB therapy.

For the clinicians, it was a shift in mindset. TB wasn’t a rare curiosity anymore; it was something they had to think about routinely when kids
presented with persistent respiratory symptoms and relevant risk factors. For the families, it was scary but also strangely relieving to finally
have an explanation and a clear treatment plan.

A Family Navigates TB Together

Consider a family who emigrated to the U.S. a few years ago from a country where TB is common. The parents worked long hours, and the kids thrived
in school and daycare. When the father developed a chronic cough and began losing weight, he brushed it off as stress and long shifts.
Only when he started feeling short of breath climbing stairs did he go to a clinic and testing confirmed active TB.

Overnight, the family’s world shifted. The health department arranged testing for everyone in the household. The youngest child had a normal chest X-ray
but a positive TB blood test, indicating latent infection. The older sibling had early signs of lung involvement. Both children started treatment;
the father began a longer, more intensive regimen.

It was a tough season many appointments, side-effect checks, scheduling around school and work but they had support: interpreters,
case managers, medication reminders, and even transportation assistance. Months later, the kids completed preventive therapy, and the father
finished his course of treatment. TB went from a terrifying unknown to a shared family victory.

Community Outbreaks and the Ripple Effect

In some areas, localized outbreaks have grabbed headlines for example, large clusters in certain counties or cities documenting dozens of active
and latent cases within a relatively short period. Behind those numbers are school nurses fielding worried questions,
daycare directors coordinating testing events, and public health workers spending long days tracking down contacts and making sure people stay on treatment.

For parents, these outbreaks can feel overwhelming: Is it safe to send my child to school? Should we travel? What does “exposure” really mean?
Clinicians often find themselves doing double duty explaining TB basics while also helping families navigate testing, imaging, and follow-up visits.

The recurring theme in these stories is not hopelessness; it’s adjustment. Communities re-learn how to take TB seriously without spiraling into panic.
People discover that “We caught it early and we’re on treatment” is a very different sentence than “We ignored it until it spread.”

What These Experiences Have in Common

Across clinics, families, and communities, several threads keep appearing:

• TB often hides behind vague, slow-burn symptoms especially in kids.
• Early testing and clear communication transform scary situations into manageable ones.
• Support systems from school nurses to public health case managers make the difference between incomplete and successful treatment.
• Stigma and misinformation still delay care; honest conversations and community education help counter that.

Rising TB cases in the U.S., especially among children, are a serious concern. But they’re also a call to action that comes with tools:
accurate tests, effective medications, and decades of public health experience. When those tools are fully funded, thoughtfully used,
and equitably accessible, TB becomes not a mysterious threat but a solvable problem even for the youngest among us.

Conclusion: An Old Foe, New Responsibility

The resurgence of TB in the United States is a reminder that infectious diseases don’t retire just because we’re tired of hearing about them.
After years of steady decline, TB cases are rising again, with notable increases among children and young adolescents. That’s the bad news.

The good news is that we’re not starting from scratch. We know how TB spreads. We have accurate tests. We have effective treatments.
We understand that pediatric TB points to recent transmission and demands rapid action. And we have public health playbooks that work
when they’re properly supported.

For families, the message isn’t “be afraid of every cough.” It’s “pay attention to persistent symptoms, understand your risk, and don’t brush off testing.”
For clinicians and policymakers, the message is clear: kids’ rising TB rates are an early warning we can’t afford to ignore.

TB may be an old foe, but with informed parents, engaged communities, and strong public health systems, it doesn’t have to be a permanent one
especially not for young children growing up in the U.S. today.

The post TB Cases Rise in U.S., Particularly Among Young Children appeared first on Everyday Software, Everyday Joy.